Biomerica's test targets cancer and osteoporosis:
This article was originally published in Clinica
Biomerica reports that it is launching a blood test for the hormone calcitonin, which can be used as a means of diagnosing cancer of the thyroid and as an adjunct for monitoring osteoporosis (bone loss). Calcitonin is produced in the thyroid gland that helps regulate blood calcium, says the Newport Beach, California firm, which plans to release the test in the US and in Europe.
You may also be interested in...
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.